Elite Pharmaceuticals (ELTP)
(Delayed Data from OTC)
$0.20 USD
+0.01 (2.83%)
Updated Aug 23, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ELTP 0.20 +0.01(2.83%)
Will ELTP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELTP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELTP
Elite Pharmaceuticals (ELTP) Posts Breakeven Q1 Earnings
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri
ELTP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Initiates Coverage of Elite Pharmaceuticals With Outperform Recommendation
Elite Pharmaceuticals' (ELTP) FY24 Earnings Up, Gross Margin Down
Other News for ELTP
Elite Pharmaceuticals, Inc. (ELTP) Q1 2025 Earnings Call Transcript
Elite Pharmaceuticals reports Q1 results
ELTP Stock Earnings: Elite Pharmaceuticals Reported Results for Q1 2025
Elite Pharmaceuticals: Navigating Stock Market Complexities
Elite Pharmaceuticals Inc (ELTP) Reports Q1 FY2025 Revenue of $18. ...